Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
October 07, 2021 08:30 ET
|
Ovid Therapeutics Inc.
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological...
Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
August 16, 2021 08:00 ET
|
Ovid Therapeutics Inc.
Company ends Q2 ’21 with cash and cash equivalents of $212.2 millionRecent appointments to Company leadership strongly position Ovid to advance current and future neuroscience programsOvid is actively...
Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities
July 08, 2021 16:30 ET
|
Ovid Therapeutics Inc.
Dr. Michael Poole to Join the Board of Directors Dr. Claude Nicaise Appointed Head of R&D and Jason Tardio Appointed Chief Operating Officer Dr. Amit Rakhit to Join the Scientific and Clinical...
Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference
July 07, 2021 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer
June 04, 2021 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board
May 26, 2021 08:00 ET
|
Ovid Therapeutics Inc.
New appointments strengthen neuroscience-focused Scientific Advisory Board NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to...
Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 16:05 ET
|
Ovid Therapeutics Inc.
Closed royalty, license and termination agreement with Takeda for soticlestat; Ovid Therapeutics received an upfront payment of $196.0 million and is eligible to receive up to $660.0 million in...
Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
May 12, 2021 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board
April 20, 2021 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...